WELLNESS
Restaurants adapt as weight-loss drugs change habits in Brazil
Mounjaro sales have exploded in Brazil. Photo: Evandro Leal/Enquadrar/Folhapress
As the use of GLP-1 drugs like Ozempic and Mounjaro for weight loss grows, countries around the world have been tracking shifts in consumer habits.
This class of drugs is based on active ingredients such as semaglutide and tirzepatide, which mimic a gut hormone to curb appetite and improve blood sugar control. Surveys conducted in the United States have found that households with at least one GLP-1 user tend to reduce their consumption of sugar, snacks, bread and alcohol.
Similar questions are now being raised by Brazilian retail chains, food brands and analysts watching long-term trends in the country's powerful sugar sector. New data illustrate how far the shift has already spread across the restaurant industry…
🔒 This was a free preview; the rest is behind our paywall
Don’t miss out! Upgrade to unlock full access. The process takes only seconds with Apple Pay or Stripe. Become a member.
Why you should subscribe
We’re here for readers who want to truly understand Brazil and Latin America — a region too often ignored or misrepresented by the international media.
Since 2017, our reporting has been powered by paid subscribers. They’re the reason we can keep a full-time team of journalists across Brazil and Argentina, delivering sharp, independent coverage every day.
If you value our work, subscribing is the best way to keep it going — and growing.
Interested in advertising with us? Get in touch.
Need a special report? We can do it.
Have an idea for an article or column? Pitch us
